Vor Biopharma Inc. (VOR) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US9290332074
Vor Biopharma Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -371.64 m USD |
| EBIT | -701.85 m USD |
| Net income | -695.98 m USD |
| Diluted EPS – continuing operations | -70.50 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Vor Biopharma Inc.
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
More stocks
- OliX PharmaceuticalsInc (226950.KQ)
- Browave (3163.TWO)
- Instalco AB (INSTAL.ST)
- Ladder Capital Corp (LADR)
- Jiangsu Zeyu Intelligent Power Co.Ltd. (301179.SZ)
- Sunwave Communications Co Ltd (002115.SZ)
- Hunan Keli Motor Co Ltd (002892.SZ)
- Empresas Lipigas S.A. (LIPIGAS.SN)
- TLG Immobilien (TLG.HM)
- Amoy Diagnostics Co Ltd (300685.SZ)
- Hyundai Development Co (294870.KS)
- Medincell SA (MEDCL.PA)
Not investment advice. All data without warranty, price as of 02.11.2026. Details in the risk notice.